ÁøÇàµÈ À§¾ÏȯÀÚ¿¡¼ FLP(5-FU, Leucovorin, Cisplatin) 3Á¦ º¹ÇÕÈÇпä¹ýÀÇ Ä¡·áÈ¿°ú¿¡ ´ëÇÑ ÀüÇâÀû Á¦2»ó Àӻ󿬱¸
Phase ¥± Trial of FLP(5-FU, Leucovorin, Cisplatin) Combination Chemotherapy for Advanced Gastric Cancer
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú¿µÀÌ
À̹®Èñ/ÇѼº¿ì/¹Ú¿ìÁ¤/±èµ¿±Ô/ÀÌÁø/¾ÈÁø¼®/ÀÌÁ¤¾Ö/¿ìÀμ÷
KMID : 0360319980300010055
Abstract
¼·Ð
±¹³» ¾Ç¼ºÁ¾¾çÁß À§¾ÏÀº ±× ¹ß»ýºóµµ³ª »ç¸Á·ü¿¡¼ ÇöÀç±îÁö Á¦ 1À§¸¦ Â÷ÁöÇÏ°í ÀÖÀ¸¸ç
Ä¡·á¹ýÀ¸·Î ¾ÆÁ÷±îÁö ±ÙÄ¡Àû ÀýÁ¦¼úÀÌ À¯ÀÏÇÑ ¿ÏÄ¡ °¡´É¼ºÀ» °¡Áø Ä¡·á¹ýÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
Áø´Ü±â ¼úÀÇ ¹ß´Þ°ú Á¶±â °ËÁøÀ¸·Î ±ÙÄ¡Àû ÀýÁ¦¼ú ½ÃÇàÀÌ Áõ°¡ÇÏ°í ÀÖÁö¸¸ Áø´Ü´ç½Ã 30¡
40%¿¡¼ ÀüÀÌ·Î ÀÎÇÏ¿© ¼ö¼úÇÒ ¼ö ¾ø°Å³ª °³º¹ÈÄ ÀýÁ¦°¡ ºÒ°¡´ÉÇÑ »óÅÂÀÌ°í, ¿Ü°úÀû ÀýÁ¦
°¡ °¡´ÉÇÏ´õ¶óµµ ´ë°³ ÁøÇàµÈ ½Ã±â·Î Áø´ÜµÇ¾î ±ÙÄ¡Àû ÀýÁ¦¼ú ½ÃÇàÈÄ ±¹¼ÒÀû Ȥ ¿ø°ÝÀå±â
ÀüÀÌ·Î ¿¹ÈÄ°¡ ÁÁÁö ¾Ê´Ù. µû¶ó¼ È¿°úÀûÀÎ Àü½ÅÀû Ä¡·á¿ä¹ýÀÌ ÇÊ¿äÇÏ´Ù ÇöÀç±îÁö À§¾ÏÀº
Àüü ¼Òȱ⠰èÅëÀÇ ¾ÏÁß Ç×¾Ï ÈÇпä¹ý¿¡ ´ëÇØ ¹ÝÀÀÀ²ÀÌ °¡Àå ³ôÀº ¾ÏÀÇ Çϳª·Î ¾Ë·ÁÁ® ÀÖ
¾î À§¾Ï¿¡ ´ëÇÑ Ç×¾ÏÈÇпä¹ýÀ¸·Î ´ÜÀÏ È¤ º´ÇÕÁ¦Á¦¿¡ ´ëÇØ ¸¹Àº ¿¬±¸°¡ ½ÃµµµÇ¾úÀ¸³ª ¹ÝÀÀ
Áö¼Ó±â°£ÀÌ Âª°í ¿ÏÀü °üÇØÀ²µµ ¸Å¿ì ³·¾Æ ¾ÆÁ÷ ¸¸Á·ÇÒ¸¸ÇÑ Ä¡·áÁ¦Á¦°¡ ¾ø¾î, ¼ö¼úÀÌ ºÒ°¡
´ÉÇϰųª ÀüÀ̼º ¶Ç´Â Àç¹ß¼º ȯÀÚ¿¡°Ô¼ Ç×¾ÏÈÇпä¹ýÀº °í½ÄÀû ¸ñÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ´Â
½ÇÁ¤ÀÌ´Ù.
À§¾Ï¿¡ ´ëÇÑ È¿°ú°¡ ÀÖ´Ù°í º¸°íµÈ ´ÜÀÏ¿ä¹ý ¾àÁ¦·Î 5-FU, mitomycin-C, adriamycin,
cisplatin, etoposide, methotrexate, ±×¸®°í nitrosouria°è ¾à¹° ÀÌ º¸°íµÇ°í ÀÖÀ¸³ª ÀÌ·¯ÇÑ ´Ü
ÀÏ ¾àÁ¦¿¡ ÀÇÇÑ Ä¡·á¼ºÀûÀº ¹ÝÀÀ·üÀÌ 20¡30% À̳»·Î ³·°í °üÇØÁö ¼Ó±â°£µµ ª¾Æ ´ÜÀϾàÁ¦
¸¦ º´ÇÕÇÑ, ÁÖ·Î 5-FU¸¦ ±Ù°£À¸·ÎÇÑ º¹ÇÕÇ×¾ÏÈÇпä¹ýÀÌ ÁøÇàµÈ À§¾ÏȯÀÚÀÇ Ä¡·á¿¡ »ç¿ëµÇ
¾ú´Âµ¥ ´ÜÀϾàÁ¦¿¡ ºñÇØ ¿ì¼öÇÑ Ä¡·á¼ºÀûÀÌ º¸°íµÇ¸é¼ ¿©·¯ °¡Áö ¾àÁ¦ÀÇ º´ÇÕ¿ä¹ýÀÌ ½Ãµµ
µÇ¾ú´Âµ¥, ƯÈ÷ ¾àÁ¦°£¿¡ ±³Â÷³»¼ºÀÌ µå¹°°í »ó½ÂÈ¿°ú°¡ Áõ¸íµÈ 5-FU¿Í cisplatinÀ» º´¿ëÇÑ
FP º¹ÇÕÈÇпä¹ýÀ¸·Î °üÇØÀ²ÀÌ 50¡60% Á¤µµ·Î ³ô°Ô º¸°íµÇ°í ÀÖ´Ù. ÇÑÆí 5-FUÀÇ Ç×¾ÏÈ¿
°ú¸¦ »ó½Â½ÃÅ°´Â »ýÈÇÐÀû Á¶Àý¹°ÁúÀÎ leucovinÀ» º´¿ëÅõ¿©½Ã 5-FUÀÇ ´Ü Åõ¿©º¸´Ù 5-FU
ÀÇ Ç×¾ÏÈ¿°ú°¡ Áõ°¡µÈ´Ù´Â »ç½ÇÀÌ ÃÖ±Ù ¿©·¯ Àӻ󿬱¸¿¡¼ º¸°íµÇ°í ÀÖ°í, 5-FU Åõ¿© ¹æ¹ý
¿¡ À־µ Áö¼ÓÁÖÀÔÀÌ bolusÁÖÀÔº¸´Ù Ç×¾ÏÈ¿°úÀÇ »ó½Â°ú °ñ¼ö¾ïÁ¦ÀÇ ºÎÀÛ¿ëÀÌ ÀûÀº °ÍÀ¸
·Î º¸°íµÇ°í ÀÖ´Ù.
ÀÌ¿¡ ÀúÀÚµîÀº ÁøÇàÀ§¾ÏȯÀÚ¸¦ ´ë»óÀ¸·Î 5-FU¿Í leucovorin ¹× cisplatinÀ» ÀÌ¿ëÇÑ FLP
º¹ÇÕÈÇÐ ¿ä¹ýÀ» »ç¿ëÇÏ¿© Ç×¾ÏÈÇÐÈ¿°ú ¹× µ¶¼ºÀ» °üÂûÇϱâ À§ÇØ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
Purpose : Advanced gastric cancer, the most common malignancy in Korea is a kind
of systemic disease. At dignosis, 50¡80% of patients have systemic cancer. Therefore,
the most patients require systemic chemotherapy. Cisplatin and 5-FU have been
suggested to be active in the treatment of gastric cancer, a high response rate was
observered with a combination of 5-FU infusion and cisplatin, and the biochemical
modulation of 5-FU by leucovorin has been demonstrated to enhance the activity of
5-FU in gastrointestinal tract cancer.
Materials and Methods : The patients with advanced gastric cancer whose disease had
relapsed or unresectable were treated with 5-FU(800 §·/cm2 12 hr IV
infusion, D 1¡5), leucovorin(20 §·/cm2 IV, D 1¡5, max. 30 §·),
cisplatin(100 §·/cm2 15min IV dripping, D1). The cycles of treatment were
repeated at 3-weeks intervals.
Results : Between Sep. 1994 and Aug. 1996, previously untreated 44 patients(39
eligible patients) were admitted to this study, the median age was 55 years (range 17¡
73) and male to female ratio was 20:19. The rate of complete remission was 5% (2/39),
the rate of partial remission was 21%(8/39). The median-response duration was 26
weeks(5'¡ 38'). The median-time to progression was 25 weeks(4+¡
62+). The range of overall survival time was from 4 to 62+ weeks. 24
weeks survival rate was 71.5% but the median survival time was not reached. The
leukopenia and anemia were the main hematologic toxicities. Non-hematologic side
effects were nausea, vomiting, diarrhea, stomatitis, peripheral neuropathy. These
toxicities were observed commonly, but tolerable. Two treatment-related deaths were
associated with sepsis.
Conclusion : Based on these results, FLP combination chemotherapy seems to be a
moderate efficacy for advanced gastric cancer with tolerable toxicities. To confirm the
efficacy further, the long-term follow up and a large scale of clinical studies are needed.
Å°¿öµå
FLP combination chemotherapy; Advanced stomach cancer;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸